Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
Status:
Completed
Trial end date:
1997-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety and effectiveness of a relatively high
dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in
treating patients with Alzheimer's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.